Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: Suppressing effects of EGCG on the development of liver lesions

Cancer Letters

Volumn 342, Issue 1, 2014, Pages 60-69

  Kochi, Takahiro ^a   Shimizu, Masahito ^a   Terakura, Daishi ^a   Baba, Atsushi ^a   Ohno, Tomohiko ^a   Kubota, Masaya ^a   Shirakami, Yohei ^a   Tsurumi, Hisashi ^a   Tanaka, Takuji ^a   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

EGCG; Hypertension; Liver fibrosis; Liver tumorigenesis; Obesity

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CYTOCHROME P450 2E1; EPIGALLOCATECHIN GALLATE; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCOLLAGEN; PROCOLLAGEN 1; STRESS ACTIVATED PROTEIN KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FATTY LIVER; HYPERTENSION; IMMUNOREACTIVITY; LIPID PEROXIDATION; LIVER CANCER; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

EGCG; HYPERTENSION; LIVER FIBROSIS; LIVER TUMORIGENESIS; OBESITY;

ANGIOTENSIN II; ANIMALS; ANTICARCINOGENIC AGENTS; CATECHIN; FATTY LIVER; GENE EXPRESSION; HYPERTENSION; INTERLEUKIN-6; LIPID PEROXIDATION; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; OBESITY; OXIDATIVE STRESS; PEPTIDYL-DIPEPTIDASE A; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 1; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 84887606375     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.031     Document Type: Article

References (52)

1. Siegel A.B., Zhu A.X. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009, 115:5651-5661.
2. Chiang D.J., Pritchard M.T., Nagy L.E. Obesity, diabetes mellitus, and liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 300:G697-702.
3. Diehl A.M. Hepatic complications of obesity. Gastroenterol. Clin. North Am. 2005, 34:45-61.
4. Rolo A.P., Teodoro J.S., Palmeira C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biol. Med. 2012, 52:59-69.
5. Szabo G., Lippai D. Molecular hepatic carcinogenesis: impact of inflammation. Dig. Dis. 2012, 30:243-248.
6. Starley B.Q., Calcagno C.J., Harrison S.A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51:1820-1832.
7. Nabeshima Y., Tazuma S., Kanno K., Hyogo H., Chayama K. Deletion of angiotensin II type I receptor reduces hepatic steatosis. J. Hepatol. 2009, 50:1226-1235.
8. Bataller R., Sancho-Bru P., Gines P., Brenner D.A. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid. Redox Signal. 2005, 7:1346-1355.
9. Matthew Morris E., Fletcher J.A., Thyfault J.P., Scott Rector R. The role of angiotensin II in nonalcoholic steatohepatitis. Mol. Cell. Endocrinol. 2012, (Epub ahead of print).
10. de Kloet A.D., Krause E.G., Woods S.C. The renin angiotensin system and the metabolic syndrome. Physiol. Behav. 2010, 100:525-534.
11. Yasui K., Hashimoto E., Komorizono Y., Koike K., Arii S., Imai Y., Shima T., Kanbara Y., Saibara T., Mori T., Kawata S., Uto H., Takami S., Sumida Y., Takamura T., Kawanaka M., Okanoue T. Japan NASH Study Group, Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2011, 9:428-433.
12. Moreno M., Ramalho L.N., Sancho-Bru P., Ruiz-Ortega M., Ramalho F., Abraldes J.G., Colmenero J., Dominguez M., Egido J., Arroyo V., Gines P., Bataller R. Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296:G147-156.
13. Wei Y., Clark S.E., Thyfault J.P., Uptergrove G.M., Li W., Whaley-Connell A.T., Ferrario C.M., Sowers J.R., Ibdah J.A. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am. J. Pathol. 2009, 174:1329-1337.
14. Hiraoka-Yamamoto J., Nara Y., Yasui N., Onobayashi Y., Tsuchikura S., Ikeda K. Establishment of a new animal model of metabolic syndrome: SHRSP fatty (fa/fa) rats. Clin. Exp. Pharmacol. Physiol. 2004, 31:107-109.
15. Ueno T., Takagi H., Fukuda N., Takahashi A., Yao E.H., Mitsumata M., Hiraoka-Yamamoto J., Ikeda K., Matsumoto K., Yamori Y. Cardiovascular remodeling and metabolic abnormalities in SHRSP.Z-Lepr(fa)/IzmDmcr rats as a new model of metabolic syndrome. Hypertens. Res. 2008, 31:1021-1031.
16. Kochi T., Shimizu M., Ohno T., Baba A., Sumi T., Kubota M., Shirakami Y., Tsurumi H., Tanaka T., Moriwaki H. Enhanced development of azoxymethane-induced colonic preneoplastic lesions in hypertensive rats. Int. J. Mol. Sci. 2013, 14:14700-14711.
17. Sae-tan S., Grove K.A., Lambert J.D. Weight control and prevention of metabolic syndrome by green tea. Pharmacol. Res. 2011, 64:146-154.
18. Grove K.A., Lambert J.D. Laboratory, epidemiological, and human intervention studies show that tea (Camellia sinensis) may be useful in the prevention of obesity. J. Nutr. 2010, 140:446-453.
19. Thielecke F., Boschmann M. The potential role of green tea catechins in the prevention of the metabolic syndrome - a review. Phytochemistry 2009, 70:11-24.
20. Shimizu M., Adachi S., Masuda M., Kozawa O., Moriwaki H. Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Mol. Nutr. Food Res. 2011, 55:832-843.
21. Shimizu M., Shirakami Y., Sakai H., Adachi S., Hata K., Hirose Y., Tsurumi H., Tanaka T., Moriwaki H. (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev. Res. (Phila.) 2008, 1:298-304.
22. Shirakami Y., Shimizu M., Adachi S., Sakai H., Nakagawa T., Yasuda Y., Tsurumi H., Hara Y., Moriwaki H. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci. 2009, 100:1957-1962.
23. Shimizu M., Sakai H., Shirakami Y., Yasuda Y., Kubota M., Terakura D., Baba A., Ohno T., Hara Y., Tanaka T., Moriwaki H. Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Prev. Res. (Phila.) 2011, 4:396-403.
24. Ogiso T., Tatematsu M., Tamano S., Tsuda H., Ito N. Comparative effects of carcinogens on the induction of placental glutathione S-transferase-positive liver nodules in a short-term assay and of hepatocellular carcinomas in a long-term assay. Toxicol. Pathol. 1985, 13:257-265.
25. Wang Z.Y., Agarwal R., Bickers D.R., Mukhtar H. Protection against ultraviolet B radiation-induced photocarcinogenesis in hairless mice by green tea polyphenols. Carcinogenesis 1991, 12:1527-1530.
26. Yasuda Y., Shimizu M., Sakai H., Iwasa J., Kubota M., Adachi S., Osawa Y., Tsurumi H., Hara Y., Moriwaki H. (-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R. Chem. Biol. Interact. 2009, 182:159-164.
27. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.C., Torbenson M.S., Unalp-Arida A., Yeh M., McCullough A.J., Sanyal A.J. Nonalcoholic steatohepatitis clinical research, design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
28. Ando N., Shimizu M., Okuno M., Matsushima-Nishiwaki R., Tsurumi H., Tanaka T., Moriwaki H. Expression of retinoid X receptor alpha is decreased in 3'-methyl-4-dimethylaminoazobenzene-induced hepatocellular carcinoma in rats. Oncol. Rep. 2007, 18:879-884.
29. Terakura D., Shimizu M., Iwasa J., Baba A., Kochi T., Ohno T., Kubota M., Shirakami Y., Shiraki M., Takai K., Tsurumi H., Tanaka T., Moriwaki H. Preventive effects of branched-chain amino acid supplementation on the spontaneous development of hepatic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Carcinogenesis 2012, 33:2499-2506.
30. Kassie F., Uhl M., Rabot S., Grasl-Kraupp B., Verkerk R., Kundi M., Chabicovsky M., Schulte-Hermann R., Knasmuller S. Chemoprevention of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ)-induced colonic and hepatic preneoplastic lesions in the F344 rat by cruciferous vegetables administered simultaneously with the carcinogen. Carcinogenesis 2003, 24:255-261.
31. Xiao J., Ching Y.P., Liong E.C., Nanji A.A., Fung M.L., Tipoe G.L. Garlic-derived S-allylmercaptocysteine is a hepato-protective agent in non-alcoholic fatty liver disease in vivo animal model. Eur. J. Nutr. 2012, 52(2013):179-191.
32. Iwasa J., Shimizu M., Shiraki M., Shirakami Y., Sakai H., Terakura Y., Takai K., Tsurumi H., Tanaka T., Moriwaki H. Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Sci. 2010, 101:460-467.
33. Yoshiji H., Noguchi R., Ikenaka Y., Kaji K., Aihara Y., Fukui H. Impact of renin-angiotensin system in hepatocellular carcinoma. Curr. Cancer Drug Targets 2011, 11:431-441.
34. Abdelmegeed M.A., Banerjee A., Yoo S.H., Jang S., Gonzalez F.J., Song B.J. Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. J. Hepatol. 2012, 57:860-866.
35. Wang Y., Ausman L.M., Russell R.M., Greenberg A.S., Wang X.D. Increased apoptosis in high-fat diet-induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax. J. Nutr. 2008, 138:1866-1871.
36. Chen H., Sullivan G., Yue L.Q., Katz A., Quon M.J. QUICKI is a useful index of insulin sensitivity in subjects with hypertension. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E804-812.
37. Tsuda H., Fukushima S., Wanibuchi H., Morimura K., Nakae D., Imaida K., Tatematsu M., Hirose M., Wakabayashi K., Moore M.A. Value of GST-P positive preneoplastic hepatic foci in dose-response studies of hepatocarcinogenesis: evidence for practical thresholds with both genotoxic and nongenotoxic carcinogens. A review of recent work. Toxicol. Pathol. 2003, 31:80-86.
38. Nabeshima Y., Tazuma S., Kanno K., Hyogo H., Iwai M., Horiuchi M., Chayama K. Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis. Biochem. Biophys. Res. Commun. 2006, 346:658-664.
39. Hirose A., Ono M., Saibara T., Nozaki Y., Masuda K., Yoshioka A., Takahashi M., Akisawa N., Iwasaki S., Oben J.A., Onishi S. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 2007, 45:1375-1381.
40. Yokohama S., Yoneda M., Haneda M., Okamoto S., Okada M., Aso K., Hasegawa T., Tokusashi Y., Miyokawa N., Nakamura K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004, 40:1222-1225.
41. Sakaida I., Hironaka K., Uchida K., Suzuki C., Kayano K., Okita K. Fibrosis accelerates the development of enzyme-altered lesions in the rat liver. Hepatology 1998, 28:1247-1252.
42. Bataller R., Gabele E., Schoonhoven R., Morris T., Lehnert M., Yang L., Brenner D.A., Rippe R.A. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285:G642-651.
43. Bataller R., Gabele E., Parsons C.J., Morris T., Yang L., Schoonhoven R., Brenner D.A., Rippe R.A. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005, 41:1046-1055.
44. Pereira R.M., dos Santos R.A., da Costa Dias F.L., Teixeira M.M., Simoes e Silva A.C. Renin-angiotensin system in the pathogenesis of liver fibrosis. World J. Gastroenterol. 2009, 15:2579-2586.
45. Moreno M., Gonzalo T., Kok R.J., Sancho-Bru P., van Beuge M., Swart J., Prakash J., Temming K., Fondevila C., Beljaars L., Lacombe M., van der Hoeven P., Arroyo V., Poelstra K., Brenner D.A., Gines P., Bataller R. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 2010, 51:942-952.
46. Rakoski M.O., Singal A.G., Rogers M.A., Conjeevaram H. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2010, 32:1211-1221.
47. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., Neuschwander-Tetri B.A., Lavine J.E., Tonascia J., Unalp A., Van Natta M., Clark J., Brunt E.M., Kleiner D.E., Hoofnagle J.H., Robuck P.R. NASH CRN, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010, 362:1675-1685.
48. Shimizu M., Fukutomi Y., Ninomiya M., Nagura K., Kato T., Araki H., Suganuma M., Fujiki H., Moriwaki H. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol. Biomarkers Prev. 2008, 17:3020-3025.
49. Bettuzzi S., Brausi M., Rizzi F., Castagnetti G., Peracchia G., Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006, 66:1234-1240.
50. Antonello M., Montemurro D., Bolognesi M., Di Pascoli M., Piva A., Grego F., Sticchi D., Giuliani L., Garbisa S., Rossi G.P. Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts. Am. J. Hypertens. 2007, 20:1321-1328.
51. Papparella I., Ceolotto G., Montemurro D., Antonello M., Garbisa S., Rossi G., Semplicini A. Green tea attenuates angiotensin II-induced cardiac hypertrophy in rats by modulating reactive oxygen species production and the Src/epidermal growth factor receptor/Akt signaling pathway. J. Nutr. 2008, 138:1596-1601.
52. Kurita I., Maeda-Yamamoto M., Tachibana H., Kamei M. Antihypertensive effect of Benifuuki tea containing O-methylated EGCG. J. Agric. Food Chem. 2010, 58:1903-1908.